Universal14 Feb 2021 14:38
Back to that word "Universal".
In this context, it is being applied to all the different variants current and future for Covid19. Having the insurance of a vaccine that attacks a constant part of the virus (the N protein) as well as the variable part (S protein) gives a lot more breathing space as new variants appear.
We are told that currently approved vaccines will at least be partly effective against mutations but if Covidity works well then that "partly effective" may be higher, perhaps much higher than current vaccines.
The unknown is how much will the high avidity of Immunobody (and now with added Avidimab) mean that the T Cells activated are more effective than current vaccines.
Also, Lindy has already stated that the N protein does not vary much over different coronaviruses. So, again if it works on Covid19, it may well be at least partially effective on the next virus. At the very least, it may be an excellent starting vaccine until Lindy and her team identify the other targets to add.
But it is not only coronaviruses that would benefit from attacking the constants. Influenza also has its constants.
https://en.wikipedia.org/wiki/Universal_flu_vaccine#:~:text=A%20universal%20flu%20vaccine%20is,modification%20from%20year%20to%20year.
So an Immunobody vaccine targeting these different constants could be on the cards.
We could be entering a very interesting period exploring the capabilities for Immunobody vaccines in a range of viruses.
This is all on top of the obvious potential for cancer trials projected to start this year.
Sign In
Follow the stocks
